Montana Medicaid does not cover Wegovy or Zepbound for weight loss

Montana Medicaid does not pay for drugs prescribed for weight reduction. Wegovy and Zepbound are covered with prior authorization only for other uses: Wegovy for cardiovascular risk reduction or MASH, and Zepbound for moderate to severe obstructive sleep apnea.12345

Mountain Pacific's Drug Prior Authorization Unit reviews GLP-1 requests for Montana Medicaid. Diabetes drugs follow the type 2 diabetes criteria; Wegovy and Zepbound are approved only for the non-weight-loss uses listed below.345678

• Diabetes GLP-1s (Ozempic, Trulicity, Victoza, Mounjaro, exenatide, liraglutide): a type 2 diabetes diagnosis, and an inadequate response to or contraindication to metformin.
• A non-preferred diabetes GLP-1 needs trials of two preferred drugs for six months each; stomach side effects do not count as a treatment failure.
• No call to the prior authorization unit is needed for a preferred diabetes GLP-1 when claims history shows a type 2 diabetes diagnosis and metformin use in the past two years.
• Wegovy injection: adults with noncirrhotic MASH with moderate to advanced liver fibrosis, or to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight.
• Wegovy tablets: adults, only to reduce the risk of major adverse cardiovascular events with established cardiovascular disease and obesity or overweight.
• Zepbound: adults with obstructive sleep apnea diagnosed by a sleep specialist, an apnea-hypopnea index of 15 or more on positive airway pressure tested in the past 12 months, a BMI of 30 or more at the sleep study, and at least six months of continuous PAP use that continues.

Coverage for other uses the FDA has approved:

• Wegovy (injection), reduction of the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight: Covered with prior authorization3
• Wegovy (injection), noncirrhotic MASH with moderate to advanced liver fibrosis, in adults: Covered with prior authorization6
• Wegovy tablets, reduction of the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight (not MASH): Covered with prior authorization5
• Zepbound, obstructive sleep apnea (AHI of 15 or more on PAP) in adults with a BMI of 30 or more at the sleep study: Covered with prior authorization7

What changed, and when:

CMS BALANCE model: CMS's BALANCE model page names no participating states, and we found no Montana DPHHS announcement that Montana has joined.11

The State Plan's 2026 Wrap Plan Document lists drugs prescribed for weight management among excluded prescription drugs, and its medical exclusions cover drugs for weight reduction or weight control. Instead, the plan offers a Healthy Weight Incentive Program.121314

Pharmacy benefit: Navitus Health Solutions (pharmacy benefit manager).

Marketplace (ACA) plans: Montana's essential health benefits benchmark plan, a Blue Cross and Blue Shield of Montana small-group PPO, excludes any drug used for weight loss.1819

On the preferred drug list dated September 10, 2026, Ozempic injections, Trulicity and Victoza are preferred, and Mounjaro, Rybelsus, Ozempic tablets, Bydureon BCise, generic exenatide and generic liraglutide are non-preferred. Coverage needs a type 2 diabetes diagnosis and a metformin trial; a non-preferred drug also needs trials of two preferred drugs for six months each.98

In 2025, Montana Medicaid paid for 22,449 GLP-1 prescriptions, $22.0 million before rebates: 20 per 1,000 residents, against 32 across the states and DC, 33rd of 51.70 It reimbursed 7 GLP-1 products that year. Every state, ranked.

CMS hides counts under 11 in a quarter, so 26 rows count as zero here and the totals are a floor.

Part D still excludes drugs used for weight loss alone: the Part D drug definition excludes drugs and uses Medicaid may exclude under SSA §1927(d)(2), which lists agents used for weight loss. Part D plans can cover GLP-1s for type 2 diabetes, MACE risk reduction (Wegovy), moderate-to-severe obstructive sleep apnea (Zepbound) and noncirrhotic MASH with fibrosis (Wegovy). For weight loss alone, the Medicare GLP-1 Bridge demonstration (July 1, 2026 – Dec 31, 2027) gives eligible Part D enrollees Foundayo, Wegovy or Zepbound KwikPen for a $50 monthly copay, outside the Part D benefit. The BALANCE Model's Part D component is not launching in 2027.4546363732402535

• Medicare GLP-1 Bridge (demonstration) (active, from 2026-07-01): Runs July 1, 2026 to December 31, 2027 (extended). Outside the Part D benefit: $50 copay per one-month supply (28 or 30 days), Part D deductible does not apply, the copay does not count toward TrOOP, no low-income subsidy. Covers Foundayo, Wegovy (injection or tablet) and Zepbound KwikPen only (not Zepbound single-dose vials or pens). Eligibility: age 18+ and, when starting GLP-1 therapy, BMI ≥35; or BMI ≥30 with heart failure with preserved ejection fraction, uncontrolled hypertension, or CKD stage 3a+; or BMI ≥27 with prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible (their Part D plan may cover GLP-1s for those conditions). Prior authorization required; valid through Dec 31, 2027 unless the patient changes GLP-1s.3233342540414243443938
• BALANCE Model — Medicare Part D component (not launching in 2027; future implementation described by CMS only as 'potential'): Originally announced to launch in Part D in January 2027. CMS's BALANCE page FAQ now refers to 'the BALANCE Model not launching in Medicare in 2027' and extends the Bridge through Dec 31, 2027 to collect data 'ahead of potential implementation of BALANCE in Part D'. No new start date is published.272925

In 2024, Medicare Part D drug plans paid for 58,251 GLP-1 claims from prescribers in Montana, $68.2 million in total drug cost.71

The lowest price among the programs that ship to every state is WellMedr: $492 for 12 months ($41 a month); $99 month to month, fees in.75 Includes a sale seen on November 5, 2026; the price returns to the standing price when it ends. The cheapest programs, ranked, or every program, ranked on our score.

Prices are what each program charged at its own checkout, fees in, with the total due for the plan length first. Compounded GLP-1s are prepared by a pharmacy to a prescription, and they are not FDA-approved; the section on compounding explains what that means.

We may earn a commission when you sign up through some links. It never changes our order or scores. How we make money

29 more programs we rank ship to fewer than 50 states, or don’t say how many. We don’t record which states they leave out, so check Montana on their sites: Embody, Collective, SnagRx, Enhanced, Direct Meds, Gala Health, GobyMeds, CoreAge Rx, Maximus Tribe, Brightmeds, SkinnyRx, Willow, Strut Health, Enhance MD, LumiMeds, VivioMD, MEDGm, MyDrHank, Zevay, LevelsRx, Hume Care, ReadyRx, Hers, Luvo Health, Remedy Meds, Hims, DudeMeds, G-Plans and Found.

The makers also sell some brand-name GLP-1s for cash, at the same price in every state, with a prescription:

These are standing prices. The Zepbound and Wegovy rankings list each dose and the terms of each offer.

Compounded GLP-1s are prepared by a pharmacy to a prescription. They are not FDA-approved: the FDA doesn’t review their safety, effectiveness or quality before they’re sold, and they are not the same as Wegovy or Zepbound. Formulas can differ from one pharmacy to the next, and some add ingredients such as vitamin B12.7677 Compounding pharmacies are licensed and inspected by state boards of pharmacy; outsourcing facilities (503B) also register with the FDA and are inspected by it. The FDA can issue warning letters when either breaks rules on safety or sterility.

The FDA’s register lists 1 outsourcing facilities (503B) in Montana, as of November 6, 2026; 0 show no inspection date and 1 were issued a Form 483.72